Bluebird bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 07:04 am EST
Share
bluebird bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 12.39 million compared to USD 0.071 million a year ago. Net loss was USD 71.73 million compared to USD 76.52 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 0.94 a year ago. Diluted loss per share from continuing operations was USD 0.66 compared to USD 0.94 a year ago.
For the nine months, revenue was USD 21.66 million compared to USD 3.53 million a year ago. Net loss was USD 123.4 million compared to USD 298.81 million a year ago. Basic loss per share from continuing operations was USD 1.15 compared to USD 3.91 a year ago. Diluted loss per share from continuing operations was USD 1.15 compared to USD 3.91 a year ago.
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).